DOD FY11 Neurofibromatosis Clinical Trial Award

The summary for the DOD FY11 Neurofibromatosis Clinical Trial Award grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Dept of the Army USAMRAA, which is the U.S. government agency offering this grant.

DOD FY11 Neurofibromatosis Clinical Trial Award: The Neurofibromatosis Research Program (NFRP) was established in 1996 to promote the understanding, diagnosis, and treatment of neurofibromatosis (NF). The vision of the FY11 NFRP is to find and fund the best research to eradicate the clinical impact of NF. The NFRP Clinical Trial Award supports research with the potential to have a major impact on the treatment or management of NF or Schwannomatosis. Funding from this award mechanism must support a clinical trial and cannot be used for preclinical research studies. A clinical trial is defined as a prospective accrual of human subjects where an intervention (e.g., device, drug, biologic, surgical procedure, rehabilitative modality, behavioral intervention, or other) is tested on a human subject for a measurable outcome with respect to exploratory information, safety, effectiveness, and/or efficacy. This outcome represents a direct effect on the human subject of that intervention or interaction.